Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL
Status:
Completed
Trial end date:
2018-10-15
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer
cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies,
such as rituximab, can block cancer growth in different ways. Some block the ability of
cancer cells to grow and spread. Others find cancer cells and help kill them or carry
cancer-killing substances to them. Radiolabeled monoclonal antibodies, such as yttrium Y 90
ibritumomab tiuxetan, can find cancer cells and carry cancer-killing substances to them
without harming normal cells. Giving combination chemotherapy together with rituximab and
yttrium Y 90 ibritumomab tiuxetan may kill more cancer cells.
PURPOSE: This phase II trial is studying giving combination chemotherapy followed by
rituximab and yttrium Y 90 ibritumomab tiuxetan to see how well it works in treating patients
with relapsed stage II, stage III, or stage IV follicular non-Hodgkin lymphoma.